What does this research mean for the field?

Question

Accepted Answer

Semaglutide reduces major adverse cardiovascular events by 32% across diverse populations, though its clinical benefit must be weighed against increased gastrointestinal and gallbladder risks, as well as uncertain cost-effectiveness. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta‑analysis

Discussion

Member takes

Overview

Key Points

Cite This Study